Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
What’s behind the meteoric rise of weight-loss drugs in Massachusetts?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
FiercePharma13d
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
The Financial Express10d
Blockbuster weight loss drug Tirzepatide coming to India soon: Benefits, weight loss potential, and side effects
This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
MM&M5d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.